ZBH
ZIMMER BIOMET HOLDINGS, INC.Evidence as of 2026-09-03Overview · ZIMMER BIOMET HOLDINGS, INC.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and t…
Management team
- Ms. Angela Main · Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia PacificFind on LinkedIn
- Ms. Keri P. Mattox · SVP and Chief Communications & Administration OfficerFind on LinkedIn
- Mr. Zeeshan Tariq · Senior VP & Chief Information OfficerFind on LinkedIn
- Mr. Sang Yi · President of Asia PacificFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The desk’s surviving claims leave a mixed picture (Mixed, +0.3 of a possible +2; was +0.3 before debate) · confidence high. Reported revenue rose from $ 1,909,100,000 in the quarter ended 31 March 2025 (Q1 2025) to $ 2,177,000,000 in the fiscal quarter ended 2026-07-30 (Q2 2026), with operating income moving from $ 292,300,000 (Q1 2025) to $ 326,100,000 (Q2 2026) and operating margins ranging roughly from 14.4% to 17.9% across the series. Net income by quarter ranged from $ 152,800,000 (30 June 2025) to $ 238,100,000 (fiscal Q1 2026, ended 2026-04-23), and shares outstanding declined from 198,181,555 as of 31 October 2025 to 190,737,689 as of 30 July 2026.
Valuation inputs that survived the desk review show price-to-free-cash-flow (TTM) at 17.52, enterprise-value-to-EBITDA (TTM) at 8.34 with EBITDA (TTM) of $ 2,345,400,000, and price-to-earnings (TTM) at 23.8 with EPS (TTM) of 4.18. The model-implied free cash flow growth rate consistent with today’s price is 5.82% per year under the stated discount and terminal assumptions, and the balance-sheet inputs cited (cash $ 410,000,000; long-term debt $ 1,000,000,000) produce an enterprise value of $ 19,568,400,056 versus a market cap of $ 18,978,400,056. News coverage uniformly notes a $ 0.24 quarterly cash dividend for the third quarter of 2026 and renewed investor attention tied to robotics narratives and some new institutional stakes.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported revenue by quarter increased from $1,909,100,000 in the quarter ended 31 March 2025 to $2,077,300,000 in the quarter ended 30 June 2025, $2,001,400,000 in the quarter ended 30 September 2025, $2,086,700,000 in the quarter ended 31 March 2026, and $2,177,000,000 in the quarter ended 30 June 2026.
XBRL companyfacts · 0001193125-26-335044Operating income by quarter showed: $292,300,000 for the quarter ended 31 March 2025; $300,000,000 for the quarter ended 30 June 2025; $351,300,000 for the quarter ended 30 September 2025; $373,200,000 for the quarter ended 31 March 2026; and $326,100,000 for the quarter ended 30 June 2026, implying operating margin (operating income / revenue) moved from roughly 15.3% (Q1 2025) to about 14.4% (Q2 2025), 17.6% (Q3 2025), 17.9% (fiscal Q1 2026, ended 31 March 2026) and ~15.0% (fiscal Q2 2026, ended 30 June 2026).
XBRL companyfacts · 0001193125-26-201710Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2 September 2026, ZBH is a constituent of the IVV ETF with a reported weight of 0.03% of the fund.
ETF constituents · market dataThe reported 0.03% weight indicates ZBH is a very small position within IVV by fund weight.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Several outlets report that Zimmer Biomet's board approved a quarterly cash dividend of $0.24 per share for the third quarter of 2026.
News · prnewswire.com · 2026-08-28The same dividend announcement was syndicated or republished by at least one major aggregator.
News · finance.yahoo.com · 2026-08-28Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-implied free cash flow growth rate that today's price would justify (under the stated discount and terminal assumptions) is 5.82% per year.
Valuation inputs · SEC XBRL + stored EOD closeweakened in debatePrice-to-free-cash-flow (TTM) is 17.52.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The evidence set shows strengthening top-line momentum alongside share-count reduction and lower long-term debt, which jointly support a favorable fundamental read. Quarterly revenue progressed from $1.91B to $2.18B across the reported periods while operating income stayed elevated in most quarters and TTM EBITDA is sizeable at $2.345B, producing an EV/EBITDA of 8.34 — a valuation metric many market participants use to identify relative value. Share repurchases reduced common shares outstanding from ~198.2M to ~190.7M within the window reported, which concentrates reported earnings per share and cash-return potential; the board-approved $0.24 quarterly dividend and reported new institutional stakes add further investor-interest context. Debt outstanding declined from a mid-period peak to $6.2775B by 30 June 2026, improving leverage dynamics on the balance-sheet inputs provided.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.33
18 surviving claims rest on 10 distinct sources; the heaviest analyst carries 33% of them, and 94% of what the desk raised survived the debate.
The surviving set rests on a moderate number of distinct sources but a substantial share of claims trace back to a small group of contributors, and one analyst carries a third of the claims — that amplifies sensitivity to errors or bias in those few inputs. The very high survival rate through debate means most claims were unrefuted internally, but that also raises the chance that shared assumptions or overlooked errors persisted; treat the read as informative but relatively fragile to a single source or filing changing.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
12 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.6 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on ZBH Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.